What is Immusoft?
Immusoft Corporation, headquartered in Seattle, Washington, is a biotechnology firm dedicated to treating diseases through its proprietary Immune System Programming platform. This innovative technology involves modifying a patient's B cells to function as cellular factories, producing gene-encoded medicines directly within the body. This approach aims to provide durable therapeutic effects for a range of conditions, positioning Immusoft at the forefront of genetic medicine and cell therapy innovation.
How much funding has Immusoft raised?
Immusoft has raised a total of $33.3M across 5 funding rounds:
Private Equity
$2.4M
Series A
$2.7M
Series B
$20M
Debt
$150K
Other Financing Round
$8M
Private Equity (2014): $2.4M, investors not publicly disclosed
Series A (2016): $2.7M, investors not publicly disclosed
Series B (2019): $20M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Other Financing Round (2023): $8M backed by The California Institute for Regenerative Medicine
Key Investors in Immusoft
The California Institute for Regenerative Medicine
The California Institute for Regenerative Medicine (CIRM) is a state agency dedicated to advancing stem cell, regenerative medicine, and gene therapy research. It focuses on accelerating the development of transformative treatments for serious diseases, with a commitment to equity and access for diverse communities. CIRM supports research from discovery to clinical trials, aiming to make groundbreaking therapies available and foster scientific innovation.
What's next for Immusoft?
With the recent major strategic investment, Immusoft is poised to accelerate the development and potential commercialization of its Immune System Programming technology. The company's focus on instructing B cells to produce therapeutic proteins represents a significant advancement in gene therapy. Future endeavors will likely involve expanding clinical trials, further refining the platform's capabilities, and potentially forging strategic partnerships to broaden the application of its disease-modifying treatments. The enterprise-level funding context suggests a trajectory towards significant scaling and market penetration.
See full Immusoft company page
